For investors seeking growth, the global healthcare sector continues to present compelling opportunities. The Polar Capital Global Healthcare investment trust employs a strategy designed to capitalize on powerful, long-term structural trends, including demographic shifts and rapid medical innovation. Its active management approach seeks to balance the stability of established industry leaders with the high-growth potential of pioneering biotechnology firms.
Portfolio Construction and Management Approach
The trust’s primary objective is capital growth, achieved through investments across the full spectrum of the healthcare value chain. Management maintains a focused portfolio, typically holding between 25 and 60 positions. This concentrated strategy involves a deliberate mix of sub-sectors, such as pharmaceuticals, medical technology, and biotechnology. As of the end of January 2026, major holdings included industry giants Eli Lilly, Roche, and AstraZeneca.
This blended portfolio aims to mitigate short-term market volatility. Larger, defensive companies provide a foundation of stability, while selected smaller biotech firms offer the possibility of outsized returns driven by technological breakthroughs. The investment team conducts ongoing reviews of sector outlooks, allowing it to adjust positions in response to valuation changes and evolving market drivers.
Should investors sell immediately? Or is it worth buying Polar Capital Global Healthcare?
Investor Communications and Performance
The trust maintains regular communication with shareholders. The most recent interim dividend of 1.00 pence per share was distributed at the end of February. Updated fact sheets, released in mid-March, provide detailed insights into recent performance and strategic asset allocation. These periodic publications, alongside comprehensive annual financial reports, serve as key resources for evaluating the management team’s execution of its stated strategy.
The long-term foundation for the trust’s approach rests on two unwavering pillars: the growing global demand for healthcare services and relentless technological progress. Ultimately, the strategy’s success hinges on the management’s skill in navigating this innovation-rich landscape, continuously making informed decisions on capital allocation between proven market leaders and emerging growth companies.
Ad
Polar Capital Global Healthcare Stock: Buy or Sell?! New Polar Capital Global Healthcare Analysis from March 21 delivers the answer:
The latest Polar Capital Global Healthcare figures speak for themselves: Urgent action needed for Polar Capital Global Healthcare investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 21.
Polar Capital Global Healthcare: Buy or sell? Read more here...











